Ruxolitinib Phosphate
Brand name: Jakafi
Rank #25 of 500 drugs by total cost
$698.1M
Total Cost
46,655
Total Claims
$698.1M
Total Cost
1,856
Prescribers
$15K
Cost per Claim
1,657
Beneficiaries
47,298
30-Day Fills
$376K
Avg Cost/Provider
25
Avg Claims/Provider
About Ruxolitinib Phosphate
Ruxolitinib Phosphate (sold as Jakafi) was prescribed 46,655 times by 1,856 Medicare Part D providers in 2023, costing the program $698.1M. At $15K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 22 | Budesonide/Formoterol Fumarate (Symbicort) | $759.4M | 1,452,561 |
| 23 | Palbociclib (Ibrance) | $755.1M | 48,329 |
| 24 | Nintedanib Esylate (Ofev) | $703.7M | 53,928 |
| 25 | Ruxolitinib Phosphate (Jakafi) | $698.1M | 46,655 |
| 26 | Cyclosporine (Restasis) | $684.1M | 723,620 |
| 27 | Linaclotide (Linzess) | $639.4M | 823,023 |
| 28 | Insulin Lispro (Humalog Kwikpen U-100) | $623.9M | 854,813 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology